Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Joy C. Hsu"'
Autor:
Lyrialle W. Han, Samira Jamalian, Joy C. Hsu, X. Rebecca Sheng, Xiaoyun Yang, Xiaoying Yang, Sharareh Monemi, Sharmeen Hassan, Rajbharan Yadav, Katie Tuckwell, Rebecca Kunder, Lin Pan, Sara Glickstein
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 755-771 (2024)
Abstract Introduction Transforming growth factor beta (TGFβ) cytokines (TGFβ1, TGFβ2, and TGFβ3) play critical roles in tissue fibrosis. However, treatment with systemic pan-TGFβ inhibitors have demonstrated unacceptable toxicities. In this stud
Externí odkaz:
https://doaj.org/article/d81ddadf28204ee39d4fd29025ec09d1
Autor:
Samira Jamalian, Michael Dolton, Pascal Chanu, Vidya Ramakrishnan, Yesenia Franco, Kristin Wildsmith, Paul Manser, Edmond Teng, Jin Y. Jin, Angelica Quartino, Joy C. Hsu, for the Alzheimer's Disease Neuroimaging Initiative
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 7, Pp 1029-1042 (2023)
Abstract There is strong interest in developing predictive models to better understand individual heterogeneity and disease progression in Alzheimer's disease (AD). We have built upon previous longitudinal AD progression models, using a nonlinear, mi
Externí odkaz:
https://doaj.org/article/3b249fe4407842a7bf2bc7d8b35b90cc
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 17 (2023)
Drug development for idiopathic pulmonary fibrosis (IPF) has been challenging due to poorly understood disease etiology, unpredictable disease progression, highly heterogeneous patient populations, and a lack of robust pharmacodynamic biomarkers. Mor
Externí odkaz:
https://doaj.org/article/7ed64f35735f4e8b93c52da7e6478dc7
Autor:
Joy C. Hsu, Felix Jaminion, Elena Guerini, Bogdana Balas, Walter Bordogna, Peter N. Morcos, Nicolas Frey
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1357-1370 (2021)
Abstract Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK‐positive non‐small cell lung cancer. Population pharmacokinetic (PK) models were developed for alectinib and its major active metabolite M4 using ph
Externí odkaz:
https://doaj.org/article/3042761aeaaf42898d02ef39ffc33fc7
Autor:
Navita L. Mallalieu, Sunethra Wimalasundera, Joy C. Hsu, Wendy Douglass, Chris Wells, Inmaculada Calvo Penades, Ruben Cuttica, Hans-Iko Huppertz, Rik Joos, Yukiko Kimura, Diana Milojevic, Margalit Rosenkranz, Kenneth Schikler, Tamas Constantin, Carine Wouters
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 17, Iss 1, Pp 1-10 (2019)
Abstract Background The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on results of a rand
Externí odkaz:
https://doaj.org/article/7f02982439724267a0d9a1e6ca5fa34f
Autor:
Iraj Hosseini, Patrick Twomey, Colby S. Shemesh, Sandhya Girish, Anand Rotte, Joy C. Hsu, Ben-Quan Shen, Benjamin Wu
Publikováno v:
Mol Ther
Tremendous innovation is underway among a rapidly expanding repertoire of promising personalized immune-based treatments. Therapeutic cancer vaccines (TCVs) are attractive systemic immunotherapies that activate and expand antigen-specific CD8(+) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b984660666735d33ee48d99dccec7dc
https://doi.org/10.1016/j.ymthe.2020.09.038
https://doi.org/10.1016/j.ymthe.2020.09.038
Autor:
Jordi Anton, Navita L. Mallalieu, Heinrike Schmeling, Gerd Horneff, Fabrizio De Benedetti, Inmaculada Calvo Penades, Alina Boteanu, Kabita Nanda, Daniel J. Lovell, Min Bao, Kamal N. Bharucha, Nicolino Ruperto, Michael Henrickson, Sunethra Wimalasundera, Johannes Roth, Manuela Pardeo, Jennifer E. Weiss, Athimalaipet V Ramanan, Nadina Rubio-Pérez, Wendy Douglass, Alberto Martini, Chris Wells, Joy C. Hsu, Hermine I. Brunner, Kirsten Minden, Markus Hufnagel, Ruben Cuttica
Publikováno v:
Rheumatology (Oxford, England)
Objectives To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular JIA (pJIA). Methods In two 52-week phase 1 b trials, s.c.-TCZ (162 mg/dose) was administered to sJIA patients every week or every 2 weeks (e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20149b973cfa7dd18ad97a9a635829fa
http://europepmc.org/articles/PMC8487273
http://europepmc.org/articles/PMC8487273
Autor:
Joy C. Hsu, Marlene Thomas, Celine Adessi, Martin Weisser, Wolfgang Jacob, Christine McIntyre, Georgina Meneses-Lorente
Publikováno v:
Cancer Chemotherapy and Pharmacology. 79:1239-1247
This study aimed at evaluating if pharmacokinetic and pharmacodynamic data from the first few patients treated with an investigational monoclonal antibody in a dose-escalation study can be used to guide the early initiation of potentially more effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727d5b6651509566962d50d1764a3560
https://doi.org/10.1007/s00280-017-3328-3
https://doi.org/10.1007/s00280-017-3328-3
Autor:
Ruben Cuttica, Rik Joos, Hans-Iko Huppertz, Chris Wells, Diana Milojevic, Joy C. Hsu, Kenneth N. Schikler, Tamás Constantin, Wendy Douglass, Sunethra Wimalasundera, Yukiko Kimura, Inmaculada Calvo Penades, Navita L. Mallalieu, Margalit Rosenkranz, Carine Wouters
Publikováno v:
Pediatric Rheumatology Online Journal
Pediatric Rheumatology Online Journal, Vol 17, Iss 1, Pp 1-10 (2019)
Pediatric Rheumatology Online Journal, Vol 17, Iss 1, Pp 1-10 (2019)
Background The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on results of a randomized co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ab131b2a064fbb539cdacd8c6a956a
https://pubmed.ncbi.nlm.nih.gov/31438986
https://pubmed.ncbi.nlm.nih.gov/31438986
Autor:
Jens Panse, Régis Peffault de Latour, Erica Winter, Junichi Nishimura, Jean-Eric Charoin, Barbara Klughammer, Joy C. Hsu, Simon Buatois, Gotanda Keisuke, Alexander Röth, Kenji Shinomiya, Antoine Soubret, Christoph Bucher, Sung-Soo Yoon, Zsolt Nagy, Alexandre Sostelly, Gregor Jordan
Crovalimab (RO7112689) is a novel anti-human C5 antibody engineered with Sequential Monoclonal Antibody Recycling Technology (SMART Ig)(Fukuzawa et al., Sci Rep. (2017) 7(1):1080), resulting in significant half-life extension and enabling infrequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7455be5df6ee8d9492f46f650737e59d
